Targeting metalloproteinases in cardiac remodeling
Journal: Journal of Cardiovascular Medicine and Cardiology (Vol.6, No. 3)Publication Date: 2019-07-31
Authors : Anestakis Doxakis Konstantinidou Polyanthi Tsepa Androniki Petanidis Savvas Zagelidou Eleni Leontari Roubini; Raikos Nikolaos;
Page : 051-060
Keywords : ;
Abstract
Uring the last years metalloproteinases as a family of proteases have been implicated in various human diseases and catalytic mechanisms of pathological disorders. Metalloproteinases can be divided into two subgroups, matrix metalloproteinases (MMPs) and adamalysins (ADAMs). The MMPs consist of 6 basic subgroups which are inhibited by the tissue inhibitors of metalloproteinase (TIMP), while ADAMs consists of approximately 40 members. It is confi rmed that metalloproteinases are an important factor for the cardiac remodeling process, interfering with the alteration of the cardiac structure induced by cardiac injury or increased haemodynamic load. The aim of this review is the analysis of the impact of metalloproteinases on cardiac remodeling and the factors affecting metalloproteinase activity. Metalloproteinases induce the remodeling process of the cardiac tissue in both benefi cial and detrimental ways. TIMPs and various administered pharmacological agents may limit the effectiveness of metalloproteinases, therefore interfering in cardiac remodeling.
Other Latest Articles
- Acute coronary syndrome- A vulnerable patient with vulnerable plaques: A case report
- Efforts to visually match 5- and 60-minute post-stress images following a single injected dose of sestamibi clearly demonstrate changes in sestamibi distribution: Demonstrating once and for all clinical recognition that sestamibi redistributes
- Effect of Out-of-Hospital Pediatric Endotracheal Intubation on survival and neurological outcome
- The Cheney Syndrome: To a man with a hammer a lot of things look like nails that need pounding. The Importance of Diet and Lifestyle Modification for treatment of Heart disease
- FMTVDM©℗ provides first patented quantitative method to accurately measure both heart disease and breast cancer on the “Health-Spectrum”
Last modified: 2019-08-08 22:15:16